Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Pfizer Seeks More M&A to Expand China Generic Drug Offerings

publication date: Feb 22, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer wants to keep pursuing “opportunities” in China and India to expand its portfolio of generic drugs. The company made the declaration soon after announcing a $545 million generic JV deal with Zhejiang Hisun Pharma. According to an unnamed Pfizer spokesperson who spoke to Reuters, Pfizer is open to business development deals of all types, including partnerships, with China and Indian pharmas to help Pfizer attain this goal. More details....

Stock Symbols: (NYSE: PFE) (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners